Takeda’s experimental epilepsy drug soticlestat has failed not one but two phase 3 trials – in Dravet syndrome and Lennox-Gastaut syndrome – throwing the future of the programme in doubt.
One of the lead candidates in Sanofi natural killer (NK) cell engager alliance with Innate Pharma has shown encouraging and durable efficacy in various haematological cancers, according to
AstraZeneca’s Calquence has been shown to improve progression-free survival in previously untreated mantle cell lymphoma (MCL), with an unprecedented trend towards improved overall survival
Johnson & Johnson’s ‘Swiss army knife’ for autoimmune diseases – FcRn inhibitor nipocalimab – has shown efficacy in Sjogren’s disease (SjD), an autoimmune condition that affects million
In the latest instalment of our clinical trials round-ups, we look at life sciences research and development announced during the week of 10th to 14th June, from early-stage onwards.
In this instalment of our clinical trials round-ups, we look at life sciences research and development announced during the week of 3rd to 7th June, from early-stage onwards.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.